A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 12 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.